List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 2063 studies with search of: t-cells
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified);   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma Nasal Type;   Enteropathy- Type T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative);   Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention: Drug: panobinostat and bortezomib
2 Recruiting Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Biological: Gene Modified T Cells;   Biological: Gene Modified T Cells and Interleukin 2
3 Active, not recruiting Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients
Condition: Neuroblastoma
Intervention: Biological: 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) w/o lymphodepletion
4 Completed Efficacy Study of T Cell Vaccination in HIV Infection
Condition: HIV Infections
Intervention: Biological: T cell vaccination
5 Terminated Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Conditions: Cutaneous T-Cell Lymphoma;   Leukemia-Lymphoma, Adult T-Cell
Intervention: Drug: Panobinostat (LBH589)
6 Recruiting Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Conditions: Leukemia;   Acute Lymphoblastic Leukemia
Intervention: Other: gene-modified T cells targeted to B-ALL tumor cells
7 Recruiting CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Biological: Infusion of CD3/CD28 stimulated T cells
8 Not yet recruiting Autologous CD19-specific T Cells Infusion
Conditions: Lymphoma;   B-Cell Lymphoma
Interventions: Procedure: Leukapheresis;   Procedure: Stem Cell Transplant;   Procedure: CD19-specific T Cell Infusion;   Drug: IL-2;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Drug: Rituximab
9 Active, not recruiting Clinical Trial of PXD101 in Patients With T-Cell Lymphomas
Conditions: Cutaneous T-Cell Lymphoma;   Peripheral T-Cell Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: belinostat
10 Recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Prostate Cancer
Intervention: Biological: Gene Modified T Cells
11 Completed Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas
Conditions: Peripheral T-Cell Lymphomas;   Non-Hodgkin Lymphoma
Intervention: Drug: Velcade
12 Recruiting Trial of Second Generation Designer T Cells in Colorectal Carcinoma
Condition: Colorectal Cancer
Intervention: Biological: Gene Modified T Cells
13 Recruiting Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.
Conditions: Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia;   B-cell Precursor Acute Lymphoblastic Leukaemia;   T-cell Non-Hodgkin's Lymphoma
Intervention: Drug: Forodesine
14 Recruiting Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants
Condition: Cytomegalovirus Infections
Intervention: Biological: CMV-Peptide-Specific T cells
15 Active, not recruiting CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
Condition: HIV-1 Infections
Interventions: Drug: IL-2 (~1.2M IU/m2);   Biological: T Cell infusion 5-10 x E9 T cells
16 Active, not recruiting T-Cell Depletion, Donor Stem Cell Transplant, and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous/Nonmalignant Condition;   Secondary Myelofibrosis
Interventions: Biological: peripheral blood lymphocyte therapy;   Drug: cyclophosphamide;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
17 Recruiting Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain
Conditions: Chronic Lymphocytic Leukemia (B-CLL);   B Cell Non-Hodgkin Lymphoma (B-NHL)
Intervention: Biological: Genetically modified T cells
18 Completed Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
Conditions: Leukemia, T-Cell;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: Yttrium-90 radiolabeled anti-Tac antibody
19 Recruiting Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: alefacept;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: pharmacological study
20 Recruiting Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Conditions: Leukemia;   Myelodysplastic Syndrome
Intervention: Biological: WT1-sensitized T cells

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services